Literature DB >> 18849282

Review. The neuropathology of kuru and variant Creutzfeldt-Jakob disease.

Catriona A McLean1.   

Abstract

A comparison of the pathological profiles of two spongiform encephalopathies with a similar presumptive route of infection was performed. Archival kuru and recent variant Creutzfeldt-Jakob disease (vCJD) cases reveal distinct lesional differences, particularly with respect to prion protein, suggesting that the strain of agent is important in determining the phenotype. Genotype analysis of the polymorphism on codon 129 reveals (in conjunction with updated information from more kuru cases) that all three genotypes (VV, MV and MM (where M is methionine and V is valine)) are detected in kuru with some preference for MM homozygosity. The presence of valine does not therefore appear to determine peripheral selection of PrPCJD. vCJD remains restricted to date to MM homozygosity on codon 129. It remains to be determined whether this genotype is dictating a shorter incubation period.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849282      PMCID: PMC2735511          DOI: 10.1098/rstb.2008.0086

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


McLean reviewed 11 archival cases of kuru held in the University of Melbourne. A comparative study of the pathology and the host genotype, particularly the naturally occurring (‘public’) polymorphism on codon 129, was conducted using these kuru cases and 11 new variant Creutzfeldt–Jakob disease (vCJD) cases from the UK. The triad of spongiform change, neuronal loss and gliosis was seen in all kuru cases in a distribution similar to that originally described, with prominent involvement of all cortical areas with the exception of the occipital cortex, hippocampus and insular gyri, and prominent changes also seen in the putamen, caudate and cerebellar cortex (figure 1; Fowler & Robertson 1958; Klatzo ; Neumann ; Kakulas ; Beck & Daniel 1979).
Figure 1

Kuru cerebellum showing spongiform change in the molecular layer, neuronal loss (Purkinje cells and granular cells) and gliosis (haematoxylin and eosin, ×200 actual magnification).

Neuropathological comparison of vCJD and kuru revealed that these diseases show distinct differences, particularly with PrPCJD immunohistochemistry, where there was a much greater PrP load in all brain areas in vCJD than in kuru, with the exception of the cerebellar granular layer (table 1). The patterns of immunohistochemical changes in the brain also varied between vCJD and kuru (table 2). A comparison of the phenotype of kuru with more recent subtyping of Creutzfeldt–Jakob disease (CJD) shows that the kuru cases resemble those cases of sporadic CJD with type 2 PrPCJD (Parchi ). McLean reported immunoperoxidase studies using the antibody 3F4 (SIGNET). A review of selected cases in 2008 using 12F10 (no. 189710 Cayman Chemical) highlights stronger and more pronounced reactivity (figure 2) than with the original 3F4 immunoperoxidase studies reported earlier.
Table 1

PrPCJD load assessed on a scale of + to +++. (Comparison of the PrPCJD load in vCJD and kuru by immunohistochemistry.)

PrPCJD loadvCJDkuru
frontal cortex++++
basal ganglia++++
thalamus++++
cerebellar molecular layer++++
cerebellar granular layer+++++–+++
basis pontis+++
spinal grey matter+++
substantia gelatinosa++
Table 2

PrPCJD patterns either present (+) or not present (−). (Comparison of the PrPCJD patterns in vCJD and kuru by immunohistochemistry.)

PrPCJD patternvCJDkuru
florid plaques+
linear/granular diffuse plaques+
dendritic++
perineuronal++
cortical L3-5 laminar+
accentuation
linear white matter in the brain stem and the spinal cord++
granular intracytoplasmic+
Figure 2

Kuru cerebellum showing strong immunoreaction with a granular pattern and plaque deposit in the granular layer and linear deposition within the molecular layer (12F10 prion protein, ×400 actual magnification).

The underlying differences in neuropathological profiles were thought to be in keeping with the different clinical features in these two disorders. Although both diseases exhibit prominent cerebellar ataxia, vCJD lacks the chronic emotional lability characteristic of kuru, and is characterized instead by psychiatric and sensory symptoms at onset with subsequent myoclonus and other movement disorders followed by dementia and akinetic mutism (Will ). The 11 cases of kuru showed a homogeneous pattern of prion protein deposition with an accentuation of cerebellar changes. Of the five cases in which the codon 129 could be assessed, there were two MM and three VV genotypes (M, methionine; V, valine; McLean ). Analyses of codon 129 in kuru have shown that those patients with an MM genotype were preferentially affected and those with MV and VV genotypes appeared to be predisposed to a lower risk of disease development and longer incubation times (Cervenáková ; Lee ; see also Hainfellner ; Lantos ). Similarly, Collinge , in a study of 11 identified patients with kuru with assessabled incubation periods of 39–56 years, found they were heterozygous at the polymorphic codon 129 and believe this genotype is associated with an extended incubation period. The presence of MM homozygotes in kuru also suggests that it is not the presence of valine 129 that determines peripheral selection of the PrPCJD, as previously postulated to account for the high frequency of a valine 129 in other cases of iatrogenic CJD (Collinge ). In vCJD, all cases to date have been MM homozygotes; however, vCJD has occurred within a very limited time frame compared with kuru (Cousens ; Collinge ). It therefore remains to be determined whether homozygosity at codon 129 dictates a shorter incubation period in vCJD. Moreover, the prolonged incubation period in kuru (over 50 years in some cases) may be significant when attempting to estimate future numbers of vCJD.
  14 in total

1.  NEUROPATHOLOGIC FINDINGS IN EXOTIC NEUROLOGIC DISORDERS AMONG NATIVES OF THE HIGHLANDS OF NEW GUINEA.

Authors:  M A NEUMANN; D C GAJDUSEK; V ZIGAS
Journal:  J Neuropathol Exp Neurol       Date:  1964-07       Impact factor: 3.685

2.  Pathology and immunocytochemistry of a kuru brain.

Authors:  J A Hainfellner; P P Liberski; D C Guiroy; L Cervénaková; P Brown; D C Gajdusek; H Budka
Journal:  Brain Pathol       Date:  1997-01       Impact factor: 6.508

3.  Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.

Authors:  P Parchi; R Castellani; S Capellari; B Ghetti; K Young; S G Chen; M Farlow; D W Dickson; A A Sima; J Q Trojanowski; R B Petersen; P Gambetti
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

4.  Predicting the CJD epidemic in humans.

Authors:  S N Cousens; E Vynnycky; M Zeidler; R G Will; P G Smith
Journal:  Nature       Date:  1997-01-16       Impact factor: 49.962

5.  Is the neuropathology of new variant Creutzfeldt-Jakob disease and kuru similar?

Authors:  P L Lantos; K Bhatia; L J Doey; S al-Sarraj; R Doshi; J Beck; J Collinge
Journal:  Lancet       Date:  1997-07-19       Impact factor: 79.321

6.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD.

Authors:  J Collinge; K C Sidle; J Meads; J Ironside; A F Hill
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

7.  Further observations on the pathology of Kuru. (A study of the two cerebra in serial section).

Authors:  B A Kakulas; A R Lecours; D C Gajdusek
Journal:  J Neuropathol Exp Neurol       Date:  1967-01       Impact factor: 3.685

8.  Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype.

Authors:  H S Lee; P Brown; L Cervenáková; R M Garruto; M P Alpers; D C Gajdusek; L G Goldfarb
Journal:  J Infect Dis       Date:  2000-12-21       Impact factor: 5.226

9.  A new variant of Creutzfeldt-Jakob disease in the UK.

Authors:  R G Will; J W Ironside; M Zeidler; S N Cousens; K Estibeiro; A Alperovitch; S Poser; M Pocchiari; A Hofman; P G Smith
Journal:  Lancet       Date:  1996-04-06       Impact factor: 79.321

10.  Kuru in the 21st century--an acquired human prion disease with very long incubation periods.

Authors:  John Collinge; Jerome Whitfield; Edward McKintosh; John Beck; Simon Mead; Dafydd J Thomas; Michael P Alpers
Journal:  Lancet       Date:  2006-06-24       Impact factor: 79.321

View more
  6 in total

1.  Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease.

Authors:  Piero Parchi; Maura Cescatti; Silvio Notari; Walter J Schulz-Schaeffer; Sabina Capellari; Armin Giese; Wen-Quan Zou; Hans Kretzschmar; Bernardino Ghetti; Paul Brown
Journal:  Brain       Date:  2010-09-07       Impact factor: 13.501

Review 2.  Kuru: genes, cannibals and neuropathology.

Authors:  Pawel P Liberski; Beata Sikorska; Shirley Lindenbaum; Lev G Goldfarb; Catriona McLean; Johannes A Hainfellner; Paul Brown
Journal:  J Neuropathol Exp Neurol       Date:  2012-02       Impact factor: 3.685

Review 3.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

4.  Introduction.

Authors:  John Collinge; Michael P Alpers
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-11-27       Impact factor: 6.237

Review 5.  Kuru: a journey back in time from papua new Guinea to the neanderthals' extinction.

Authors:  Pawel P Liberski
Journal:  Pathogens       Date:  2013-07-18

Review 6.  Kuru, the First Human Prion Disease.

Authors:  Paweł P Liberski; Agata Gajos; Beata Sikorska; Shirley Lindenbaum
Journal:  Viruses       Date:  2019-03-07       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.